David P. Roberson, PhD, MBA

David P. Roberson, PhD, MBA has a diverse range of work experience in the fields of biotech, healthcare, and investment banking.

David P. is currently the Co-Founder and CEO of Blackbox Bio, a position they have held since April 2021.

In May 2022, they co-founded Cacti.

From August 2016 to March 2021, they served as the Co-Founder and COO of Blue Therapeutics, where they played a key role in strategic planning, fundraising, preclinical mapping, and business development. David P. raised nearly $7 million in non-dilutive funding for the company.

Prior to that, David was the Scientific Co-Founder of Nocion Therapeutics and an HMS Business Development Fellow at Harvard Medical School from 2015 to 2017. David P. was responsible for early-stage commercialization activities and securing R&D funding agreements.

From 2013 to 2014, they worked as a Data Analyst on a DARPA-funded AI project at the Massachusetts Institute of Technology. David P. provided linguistic coding for training AI algorithms.

In 2012, they worked as a Graduate Teaching Fellow and Teaching Fellow at Harvard University, teaching courses on neurobiology and drug addiction.

David P. also has experience as a Drug Development Fellow at Massachusetts General Hospital from 2008 to 2009, where they designed and conducted non-clinical studies for experimental analgesics.

Earlier in their career, David worked as a Clinical Research Coordinator at the Center for Attention Research and as a Tissue Procurement Coordinator and Team Leader at ARORA, where they were responsible for the procurement of transplantable human tissue.

David P. began their career as an Investment Banking Associate at Crews & Associates, where they established new investor relationships and conducted research on fixed income securities.

Overall, David P. Roberson's work experience demonstrates their expertise in biotech, healthcare, research, and business development.

David P. Roberson, PhD, MBA has an extensive education history. David P. began their academic journey at Harding University, where they obtained a Bachelor of Arts (BA) in Psychology from 1991 to 1996. After this, they pursued a Master of Business Administration (MBA) from Harding University, which they completed from 2003 to 2005.

David P.'seducational pursuits then shifted towards the medical field. From 2006 to 2010, they attended Technion - Israel Institute of Technology, where they studied in Medical School. Although the specific degree obtained during this period is not mentioned, it can be assumed to be an undergraduate degree in medicine due to the nature of the institution.

Dr. Roberson continued their education at Harvard University, from 2010 to 2015, where they earned a Doctor of Philosophy (PhD) in Neuroscience. This formalized their expertise in the field.

After completing their PhD, Dr. Roberson embarked on a Postdoctoral Fellowship in Drug Development at Harvard Medical School. This fellowship lasted from 2015 to 2019 and focused on the specialized area of drug development.

In 2019, they transitioned into a new role at Harvard Medical School, becoming an Instructor of Neurology. Although specific information about the field of study within this role is not provided, it can be inferred that their knowledge and expertise in neuroscience are being utilized.

Overall, Dr. David P. Roberson's education history showcases a wide range of academic pursuits, spanning from psychology and business administration to neuroscience and medicine.